14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CAMP vs CLYM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Climb Bio, Inc. (CLYM) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (45.7/100 HOLD vs. 43.9/100 HOLD) after splitting the core matrix 5–2 (led by Profitability & Quality), while CAMP wins 3–1 across the 6-pillar growth and valuation breakdown. CAMP trades at $3.95 (N/M Forward P/E, -991.8% operating margin) versus CLYM at $9.63 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: CLYM earns the overall head-to-head edge with a stronger Unified Composite Score (45.7/100 HOLD vs. CAMP 43.9/100 HOLD) and 1.52β · 112% Vol risk profile, whereas CAMP leads top-line expansion (+138.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9); meanwhile CLYM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CAMP vs CLYM. Trailing 12-month operating profitability (CAMP -991.8% vs CLYM 0.0%) and valuation multiples (CAMP N/M vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $608.5M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CAMP vs CLYM Key Questions & Quantitative Answers
As of Nov 17, 2026, Climb Bio, Inc. (CLYM) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (45.7/100 HOLD vs. 43.9/100 HOLD) after splitting the core matrix 5–2 (led by Profitability & Quality), while CAMP wins 3–1 across the 6-pillar growth and valuation breakdown. CAMP trades at $3.95 (N/M Forward P/E, -991.8% operating margin) versus CLYM at $9.63 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: CLYM earns the overall head-to-head edge with a stronger Unified Composite Score (45.7/100 HOLD vs. CAMP 43.9/100 HOLD) and 1.52β · 112% Vol risk profile, whereas CAMP leads top-line expansion (+138.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9); meanwhile CLYM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CAMP leads the Growth & Scale pillar: CAMP posts +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin), compared with CLYM at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CAMP generates $5.3M in USD-normalized revenue versus N/A for CLYM. In operating R&D and SG&A reinvestment, CAMP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CLYM.
CAMP screens cheaper on headline valuation multiples. CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin), whereas CLYM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAMP (-146.1% ROE) versus CLYM (-29.3% ROE) capital efficiency.
In options market volatility and institutional positioning, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 94% Vol realized risk). By comparison, CLYM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 112% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.